

Press Release



Announcement of a co-promotion agreement for the in-vitro diagnostics [Rapid SP® «Chlamydia»]

TOKYO, January 16th, 2018 – ASKA Pharmaceutical Co., Ltd. (Head Office: Minato-ku, Tokyo, President: Takashi Yamaguchi, hereinafter "ASKA") and DS Pharma Biomedical Co., Ltd. (Head Office: Suita-shi, Osaka, President: Susumu Nakajima, hereinafter "DS Pharma Biomedical") have announced that the two companies have entered into a co-promotion agreement starting from February 2018 regarding the in-vitro diagnostics [Rapid SP® «Chlamydia»] which is manufactured and marketed by DS Pharma Biomedical.

[Rapid SP® «Chlamydia»] is an in-vitro diagnostic drug that DS Pharma Biomedical has been marketing since October 2010. It is a POCT* that can be used to test for chlamydia infection with a reaction time of 10 minutes. This allows for same day testing as well as initiating the appropriate treatment on the same day.

Genital chlamydial infection is the most common sexually transmitted disease reported by the Ministry of Health, Labour and Welfare and is routinely tested in obstetrics and gynecology and urology. Chlamydia infection among young women can lead to infertility as well as miscarriages, and if pregnant women give birth during a chlamydia infection, vertical infection can cause neonatal conjunctivitis as well as pneumonia. Even in men, chlamydial infection can cause urethritis and epididymitis, and if one partner becomes infected, they can re-infect one another if not treated appropriately. Thus, it is clinically very important to receive the appropriate treatment.

DS Pharma Biomedical and ASKA aim to further contribute to healthcare via providing necessary in-vitro diagnostics as well as through the co-promotion of the above in-vitro diagnostic product.

*POCT: "point of care testing". Clinical testing conducted next to the patient (Bedside).

[About DS Pharma Biomedical Co., Ltd.]

DS Pharma Biomedical is a subsidiary and owned 100% by Sumitomo Dainippon Pharma and imports and sells in-vitro diagnostics, medical devices, cell culture-related products, and research reagents as well as devices. In addition to its current businesses, DS Pharma Biomedical is also working on AG business within Japan.

For more information, please visit <http://www.dspbio.co.jp/>

[About ASKA Pharmaceutical Co., Ltd.]

Since its establishment in 1920, ASKA Pharmaceutical has been a specialty pharma that focuses on, and provides products related to therapeutic areas in Internal medicine, Obstetrics and gynecology, and Urology, and is expanding its lineup.

With this co-promotion agreement starting from February 2018, ASKA aims to further improve and enhance its presence.

For more information, please visit <https://www.aska-pharma.co.jp/english/>

[Inquiries regarding this matter]

DS Pharma Biomedical Co., Ltd.

TEL: +81-6-6337-5941

ASKA Pharmaceutical Co., Ltd.

TEL: +81-3-5484-8366